We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+34.93%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$132M
AUM Growth
+$31.8M
Cap. Flow
+$10.8M
Cap. Flow %
8.18%
Top 10 Hldgs %
55.55%
Holding
79
New
8
Increased
18
Reduced
14
Closed
10

Top Buys

Rank Stock Value
1
KLAC icon
KLA
KLAC
+$5.63M
2
CMPX icon
Compass Therapeutics
CMPX
+$2.76M
3
FOLD
Amicus Therapeutics
FOLD
+$1.6M
4
BCYC
Bicycle Therapeutics
BCYC
+$1.16M
5
GPCR icon
Structure Therapeutics
GPCR
+$837K

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$1.13M
2
ELUT icon
Elutia
ELUT
+$830K
3
HROW icon
Harrow
HROW
+$753K
4
AXGN icon
Axogen
AXGN
+$608K
5
XNCR icon
Xencor
XNCR
+$550K

Sector Composition

Rank Sector Weight
1 Healthcare 76.79%
2 Technology 17.82%
3 Energy 4.7%
4 Materials 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
51
BridgeBio Pharma
BBIO
$15.9B
$451K 0.34%
8,688
+3,688
+74% +$180K
AVTX icon
52
Avalo Therapeutics
AVTX
$975M
$394K 0.3%
+31,000
New +$267K
GH icon
53
Guardant Health
GH
$19.8B
$375K 0.28%
+6,000
New +$326K
PHVS icon
54
Pharvaris
PHVS
$2.4B
$370K 0.28%
+14,847
New +$329K
ZBIO
55
Zenas BioPharma
ZBIO
$1.97B
$366K 0.28%
16,500
– –
GOSS icon
56
Gossamer Bio
GOSS
$71.2M
$363K 0.27%
138,176
– –
APLS
57
DELISTED
Apellis Pharmaceuticals
APLS
$317K 0.24%
14,000
– –
VTYX
58
DELISTED
Ventyx Biosciences
VTYX
$307K 0.23%
98,827
+70,027
+243% +$186K
CADL icon
59
Candel Therapeutics
CADL
$718M
$306K 0.23%
60,000
– –
KIDS icon
60
OrthoPediatrics
KIDS
$501M
$296K 0.22%
16,000
-10,000
-38% -$206K
TELA icon
61
TELA Bio
TELA
$32.2M
$231K 0.17%
155,000
– –
NKTR icon
62
Nektar Therapeutics
NKTR
$2.22B
$229K 0.17%
+4,021
New +$133K
XLV icon
63
State Street Health Care Select Sector SPDR ETF
XLV
$41.3B
$208K 0.16%
+1,498
New +$203K
KPTI icon
64
Karyopharm Therapeutics
KPTI
$168M
$183K 0.14%
27,985
– –
APLT
65
DELISTED
Applied Therapeutics
APLT
$136K 0.1%
225,000
-55,000
-20% -$25.9K
CGEM icon
66
Cullinan Oncology
CGEM
$1.08B
$119K 0.09%
20,000
– –
IFRX icon
67
InflaRx
IFRX
$268M
$67K 0.05%
50,000
– –
ALMS
68
Alumis Inc
ALMS
$3.58B
$39.9K 0.03%
10,000
– –
ZNTL icon
69
Zentalis Pharmaceuticals
ZNTL
$359M
$25.7K 0.02%
17,000
– –
APVO icon
70
Aptevo Therapeutics
APVO
$5.96M
– –
-556
Closed -$30.5K
AXDX
71
DELISTED
Accelerate Diagnostics
AXDX
– –
-325,239
Closed -$2.08K
BCRX icon
72
BioCryst Pharmaceuticals
BCRX
$2.34B
– –
-40,000
Closed -$358K
BPMC
73
DELISTED
Blueprint Medicines
BPMC
– –
-2,700
Closed -$346K
COGT icon
74
Cogent Biosciences
COGT
$6.55B
– –
-40,000
Closed -$287K
MLTX icon
75
MoonLake Immunotherapeutics
MLTX
$1.59B
– –
-8,000
Closed -$378K
1 2
3
4

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Birchview Capital held 79 positions worth $132M, up 32% from $101M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Birchview Capital deployed $10.8M of net new capital in Q3 2025, opening 8 new positions and adding to 18 existing holdings. Its largest new stake was Compass Therapeutics: 872,938 shares worth $3.06M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 79% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $1.13M trimmed.

  • Birchview Capital's largest Q3 2025 buy was Compass Therapeutics: 872,938 shares worth $3.06M.
  • Birchview Capital added most to KLA in Q3 2025, an estimated $5.63M increase.
  • Birchview Capital's biggest Q3 2025 reduction was Travere Therapeutics, cutting an estimated $1.13M.
  • Birchview Capital fully exited Xencor in Q3 2025, selling an estimated $550K.
  • Birchview Capital's ten largest holdings make up 56% of its $132M portfolio in Q3 2025.
  • Birchview Capital opened 8 new positions and closed 10 in Q3 2025.
  • Birchview Capital's portfolio value rose 32% quarter-over-quarter to $132M.

Based on Birchview Capital's 13F filing for Q3 2025, filed 13 Nov 2025.